The company said it will use part of the proceeds to repurchase some of its senior notes due in January 2025, and the rest for corporate purposes.
The company said test volume for its Cologuard colorectal cancer test rose 66 percent during the quarter to 292,000.
The startup, which was founded by two Washington University researchers and a Wharton MBA, is looking to take a big bite out of Cologuard's market.
The test, which searches for fragments of DNA 200 basepairs or longer that are characteristic of diseased mucosa, may eventually compete with diagnostics like Exact Sciences' Cologuard.
The index, which outperformed the Dow Jones and the Nasdaq this month, gained 11 percent and rebounded from its 11 percent loss in December.
A busy second day of the JP Morgan conference saw Thermo Fisher's Marc Casper discuss the firm's R&D focus and Exact Sciences' Kevin Conroy discuss plans for Cologuard sales growth.
The company said it completed approximately 292,000 Cologuard tests during the fourth quarter.
Test volume for the firm's Cologuard colorectal cancer screening test rose 49 percent year over year during the quarter.
Biomatrica's sample collection tubes ensure quality preservation of circulating tumor DNA and cells, promoting high-quality liquid biopsy results, Exact said.
Pfizer will join Exact's sales reps to increase adoption of the colorectal cancer test; Wall Street reacted by sending Exact's shares up sharply.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.